Researchers from the University of Minnesota have developed a 3D spherical microfluidic device. Here, Dr Ruitao Su explains how the new device can be used in drug discovery and development.
List view / Grid view
Drug Target Review brings you five of the most recent developments in three-dimensional (3D) bioprinting.
Dmytro Spilka explains why UK biotech companies are receiving increasing levels of investment and why this trend is likely to continue.
An airway-on-a-chip has been used to show that amodiaquine inhibits SARS-CoV-2 infection, making it a potential COVID-19 therapeutic.
The latest ebook from Sartorius takes an in-depth look at the technologies and techniques that have been integral to developing the antibody discovery workflow, featuring a host of expert articles, interviews and application notes.
The exciting potential of immunotherapy for cancer treatment continues its exploration and here, Drug Target Review investigates three of the latest pre-clinical developments in immuno-oncology research.
A team from the University of Texas at Dallas has shown that a novel buffer solution is effective at stabilising the liposomes and lipid nanoparticles in certain COVID-19 vaccines.
Dr James Woody discusses off-patent indications for anti-TNF to address unmet patient needs in pain, inflammation and beyond.
Dr Brittany Busse discusses why COVID-19 can influence the onset of diabetes and how this could shape the development of therapeutics.
Dr Praveen Prathapan explains why broad-spectrum therapeutics need to be identified to provide a safety net against pandemics, including COVID-19.
Dr Sam Liver, Manager of the High-Throughput Molecular Discovery Laboratory at the Rosalind Franklin Institute, explains how lab automation in the form of machine learning and high‑throughput experimentation (HTE) can be implemented to enhance productivity in autonomous molecular discovery.
Sahm Nasseri discusses promising pre-clinical results of an RNA-based therapeutic developed to treat retinitis pigmentosa type 11.
Although a cure for HIV continues to elude scientists, strategies to control the virus and immunise people are developing at rapid pace. Here, Drug Target Review’s Victoria Rees discusses why researchers are focusing on antibodies as approaches to combat HIV and highlights recent findings from two pre-clinical studies into how…
In this article, Dr Lien Lybaert describes how the innate and adaptive immune system work together to produce an effective and durable antitumour response. She explains why the best strategy for personalised cancer therapy is therefore to identify major histocompatibility (MHC) binding epitopes to cover the full antigenic repertoire of…
In this Q&A, Dr Taha Merghoub discusses how a combination of glycolytic-pathway inhibition and immune checkpoint blockade using anti-CTLA-4 in patients with highly glycolytic tumours could present a personalised approach for immuno-oncology.